- Investing Ideas
- /
- Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks
Global Pharmaceuticals & Biotech Strong Balance Sheet Stocks
UPDATED Jun 04, 2023
U.S. Strong Balance Sheet Stocks: companies with a Health score of at least 4, ordered by Health score.
649 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| BNTXBioNTech | US$108.13 | 2.7% | -32.1% | US$26.1b | US$160.66 | PE3.9x | E-50.6% | n/a | ||
| QGENQiagen | US$46.48 | 0.9% | 0.5% | US$10.6b | US$53.92 | PE21x | E6.3% | n/a | ||
| NRIXNurix Therapeutics | US$10.92 | 11.5% | 3.1% | US$518.1m | US$29.38 | PS12.4x | E10.9% | n/a | ||
| APVOAptevo Therapeutics | US$1.60 | -3.0% | -68.9% | US$11.7m | US$14.50 | PE0.7x | E20.1% | n/a | ||
| PCVXVaxcyte | US$50.73 | 3.6% | 155.4% | US$4.8b | US$66.29 | PB5x | E-3.9% | n/a | ||
| AMPHAmphastar Pharmaceuticals | US$46.70 | 5.8% | 24.6% | US$2.3b | US$44.33 | PE24.2x | E10.4% | n/a | ||
| SAVACassava Sciences | US$23.23 | -1.4% | -16.8% | US$969.8m | US$124.00 | PB4.8x | E5.5% | n/a | ||
| PMCBPharmaCyte Biotech | US$3.16 | 0.3% | 47.7% | US$53.1m | n/a | PB0.7x | n/a | n/a | ||
| FDMT4D Molecular Therapeutics | US$18.36 | 4.3% | 147.1% | US$631.3m | US$38.43 | PS285.9x | E-16.3% | n/a | ||
| DRMADermata Therapeutics | US$1.52 | -6.2% | -85.8% | US$4.8m | US$4.00 | PB0.6x | E-3.2% | n/a | ||
| RVMDRevolution Medicines | US$25.57 | -0.2% | 34.4% | US$2.7b | US$31.44 | PS78.1x | E1.9% | n/a | ||
| EXELExelixis | US$19.19 | 0.3% | 2.2% | US$6.2b | US$24.99 | PE40.6x | E27.7% | n/a | ||
| PROKProKidney | US$11.51 | 4.8% | 16.7% | US$2.7b | US$15.20 | PE16.3x | E8.1% | n/a | ||
| NTLAIntellia Therapeutics | US$40.96 | 5.1% | -9.4% | US$3.6b | US$89.74 | PS67.5x | E12.1% | n/a | ||
| ALVRAlloVir | US$3.96 | 1.8% | 2.1% | US$356.1m | US$21.75 | PB1.8x | E52.9% | n/a | ||
| SQLSeqLL | US$0.46 | -8.9% | -37.2% | US$6.4m | n/a | PS205.8x | n/a | n/a | ||
| MNPRMonopar Therapeutics | US$0.99 | 7.9% | -52.2% | US$13.1m | US$9.25 | PB1.5x | E22.1% | n/a | ||
| TALSTalaris Therapeutics | US$2.53 | -9.0% | -71.1% | US$106.7m | US$7.50 | PB0.7x | E38.8% | n/a | ||
| CAPRCapricor Therapeutics | US$4.55 | 0.9% | 32.3% | US$115.0m | US$15.00 | PS20.8x | E58.0% | n/a | ||
| SWTXSpringWorks Therapeutics | US$27.34 | -1.4% | 25.9% | US$1.7b | US$56.00 | PB3.4x | E22.6% | n/a | ||
| CORTCorcept Therapeutics | US$23.26 | -3.0% | 8.6% | US$2.4b | US$30.67 | PE25.1x | E26.2% | n/a | ||
| SLNSilence Therapeutics | US$5.40 | -5.6% | -38.6% | US$194.5m | US$41.84 | PS6.7x | E-30.5% | n/a | ||
| MEIPMEI Pharma | US$7.50 | 2.2% | -30.5% | US$50.0m | US$28.00 | PB1.5x | E-8.9% | n/a | ||
| BBLGBone Biologics | US$0.18 | 3.1% | -87.9% | US$3.1m | US$4.50 | PB1.1x | E-34.7% | n/a |